Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Oct 1, 2010 → Nov 25, 2016
NCT ID
NCT01008150About Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide
Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide is a phase 2 stage product being developed by Puma Biotechnology for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01008150. Target conditions include Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01008150 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Cancer